AstraZeneca boss Pascal Soriot’s pay rises to £17.7m
Pascal Soriot, CEO of AstraZeneca, received a £17.7 million total remuneration, marking a 6.4% increase from the previous year, amid controversies regarding investment cuts in the UK.
The patent for the most expensive diabetes drug has been revoked. Are cheaper alternatives closer to reimbursement?
A patent for dapagliflozin, a leading diabetes medication, has been revoked, potentially paving the way for cheaper generic versions to be reimbursed in Poland.
China charges former AstraZeneca executive – what it means for global pharmaceutical firms
China has formally charged former AstraZeneca executive Leon Wang with multiple offenses, highlighting pressures facing foreign pharmaceutical companies in a tightening regulatory environment.
AstraZeneca's thrombosis mystery has finally been solved
A new international working group has identified the molecular mechanism behind the thrombosis risk linked to AstraZeneca and Johnson & Johnson COVID-19 vaccines, paving the way to preventing this rare side effect in the future.
Astra Zeneca's Thrombus Mystery Finally Solved
The international research team has identified the exact molecular mechanism behind the thromboembolic risks associated with Astra Zeneca and Johnson & Johnson vaccines during the pandemic.
COPD a significant risk factor for lung cancer – Awareness campaign for Lung Care
AstraZeneca launches an initiative aimed at promoting lung health, focusing on the connection between Chronic Obstructive Pulmonary Disease (COPD) and lung cancer.
Awareness campaign for lung care
AstraZeneca has launched a strong initiative to promote lung health via an awareness campaign and collaborations with prominent health organizations in Greece.
AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment
AstraZeneca's CEO recognizes a new NHS drug pricing deal as a positive move, yet it will not lead to the resumption of a £200m investment in the UK.
AstraZeneca profit rises as cancer drug sales grow
AstraZeneca reported a 45% increase in net profit for 2025, driven by robust sales of cancer drugs and expansion in the U.S. and China.
A pioneering ruling considers the sequelae of a defective Covid-19 vaccine as a work accident
A groundbreaking ruling by the Superior Court of Justice of Catalonia recognizes the adverse effects of a defective AstraZeneca Covid-19 vaccine as a work accident for a teacher.